Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)
Summary: Thermo Fisher is expected to have near zero revenue and earnings growth in 2024
Summary: Thermo Fisher is expected to have near zero revenue and earnings growth in 2024
Summary: Thermo Fisher Scientific Inc. is being downgraded to a potential Sell opportunity near its
Summary: Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual
Summary: Thermo Fisher Scientific reported $44.98 billion revenue in 2022 with a breakup of 29%
Summary: Thermo Fisher Scientific revises full-year revenue guidance due to sluggish growth in China and
Summary: Thermo Fisher Scientific Inc. continues to pursue acquisitions to add to its growing portfolio.
Summary: Thermo Fisher has normalized its growth spurred by the pandemic-induced boom. It has made
Summary: Thermo Fisher Scientific is facing temporary revenue headwinds due to reduced COVID-19-related sales and
Summary: Thermo Fisher Scientific Inc. has established itself as a leader in their industry. Their
Summary: Thermo Fisher Scientific is a top wealth compounder with strong performance in the medical